Skip to main content
Log in

Clinical Pharmacokinetics of Bambuterol

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Bambuterol, a biscarbamate ester prodrug of the β2 adrenergic agonist terbutaline, has been approved for the treatment of asthma in 28 countries. It is available in 10 and 20mg (25 and 50 μmol) tablets as the hydrochloride salt.

Bambuterol is stable to presystemic elimination and is concentrated by lung tissue after absorption from the gastrointestinal tract. The prodrug is hydrolysed to terbutaline primarily by butyrylcholinesterase, and lung tissue is capable of this metabolic pathway. It is also oxidatively metabolised to products which can be hydrolysed to terbutaline.

Peak terbutaline plasma concentrations occur 3.9 to 6.8 hours after bambuterol ingestion, and the peak: trough terbutaline concentration ratio is lower than that after ingestion of terbutaline. Older patients have a greater area under the plasma concentration-time curve for terbutaline over a dose interval at steady-state.

Whether genetic variations in the expression of butyrylcholinesterase alter therapeutic response remains to be determined. The efficacy of bambuterol has been demonstrated to last for 24 hours after ingestion; once-daily administration in the evening is recommended. Maximum therapeutic benefit requires more than 1 week of treatment.

Except for the suppression of plasma butyrylcholinesterase, the adverse effect profile of bambuterol is essentially that of a β2 agonist and is best correlated with circulating terbutaline concentration in plasma. Plasma butyrylcholinesterase activity returns to control values approximately 2 weeks after discontinuation of treatment with bambuterol.

This new drug provides oral β2 agonist therapy in a more convenient form than was available previously, and may have a better therapeutic: toxic ratio than terbutaline.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sitar DS, Aoki FY, Warren CP, et al. A placebo-controlled dose-finding study with bambuterol in elderly patients with asthma. Chest 1993; 103: 771–6

    Article  PubMed  CAS  Google Scholar 

  2. Svennson L-Å, Tunek A. The design and bioactivation of presystemically stable prodrugs. Drug Metab Rev 1988; 19: 165–94

    Article  Google Scholar 

  3. Tunek A, Svennson L-Å. Bambuterol, a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterases in human blood. Drug Metab Dispos 1988; 16: 759–64

    PubMed  CAS  Google Scholar 

  4. Tunek A, Levin E, Svennson L-Å. Hydrolysis of H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro. Biochem Pharmacol 1988; 37: 3867–76

    Article  PubMed  CAS  Google Scholar 

  5. Tunek A, Hiertberg E, Mogensen JV. Interactions of bambuterol with human serum cholinesterase of the genotypes EuEu (normal), EaEa (atypical) and EuEa. Biochem Pharmacol 1991; 41: 345–8

    Article  PubMed  CAS  Google Scholar 

  6. Persson H, Olsson T. Some pharmacological properties of terbutaline (INN), 1-(3,5-dihydroxyphenyl)-2-(t-butylamino)-ethanol. A new sympathomimetic β-receptor-stimulating agent. Acta Med Scand 1979; Suppl. 512: 11–9

    Google Scholar 

  7. Brogden RN, Speight TM, Avery GS. Terbutaline: a preliminary report of its pharmacological properties and therapeutic efficacy in asthma. Drugs 1973; 6: 324–32

    Article  PubMed  CAS  Google Scholar 

  8. Nilsson HT, Persson K, Tegnér K. The metabolism of terbutaline in man. Xenobiotica 1972; 2: 363–75

    Article  PubMed  CAS  Google Scholar 

  9. Lefrink JG, Wagemaker-Engels I, Maees RAA, et al. Quantitative analysis of terbutaline in serum and urine at therapeutic levels using gas chromatography-mass spectrometry. J Chromatogr 1977; 143: 299–305

    Article  Google Scholar 

  10. Clare RA, Davies DS, Baillie TA. The analysis of terbutaline in biological fluids by gas chromatography electron impact mass spectrometry. Biomed Mass Spectrom 1979; 6: 31–7

    Article  PubMed  CAS  Google Scholar 

  11. Jacobsson S-E, Jönsson S, Lindberg C, et al. Determination of terbutaline in plasma by gas chromatography chemical ionization mass spectrometry. Biomed Mass Spectrom 1980; 7: 265–8

    Article  PubMed  CAS  Google Scholar 

  12. Edholm L-E, Kennedy B-M, Bergquist S. Automated analysis of terbutaline (Bricanyl®) in human plasma with liquid chromatography and electrochemical detection using column switching (multidimensional chromatography). Chromatographia 1982; 16: 341–4

    Article  CAS  Google Scholar 

  13. Edholm L-E, Kennedy B-M, Bergquist S. Multidimensional column liquid chromatography with electrochemical detection for the analysis of terbutaline in human plasma. Eur J Resp Dis 1984; 65 Suppl. 134: 33–40

    Google Scholar 

  14. Kennedy B-M, Blomgren A, Deholm L-E, et al. Quantitative determination of terbutaline in human plasma after administration of bambuterol using coupled columns and electrochemical detection. Chromatographia 1987; 24: 895–9

    Article  CAS  Google Scholar 

  15. Sitar DS, Piafsky KM, Ogilvie RI. The relative bioavailability of terbutaline (Bricanyl®) elixir and tablet formulations. Curr Ther Res 1976; 19: 266–73

    PubMed  CAS  Google Scholar 

  16. Nyberg L. Pharmacokinetic parameters of terbutaline in healthy man: an overview. Eur J Respir Dis 1984; 65 Suppl. 134: 149–60

    Google Scholar 

  17. Pedersen BK, Laursen LC, Gnosspelius Y, et al. Bambuterol: effects of a new anti-asthmatic drug. Eur J Clin Pharmacol 1985; 29: 425–7

    Article  PubMed  CAS  Google Scholar 

  18. Vilsvik JS, Langaker O, Persson G, et al. Bambuterol: a new long acting bronchodilating prodrug. Ann Allergy 1991; 66: 315–9

    PubMed  CAS  Google Scholar 

  19. Sandström T, Åsander L, Clemmensen IH, et al. Bambuterol: clinical effects of different doses of a long-acting bronchodilator prodrug. Respiration 1988; 53: 31–6

    Article  PubMed  Google Scholar 

  20. Holstein-Rathlou N-H, Laursen LC, Madsen F, et al. Bambuterol: dose response study of a new terbutaline prodrug in asthma. Eur J Clin Pharmacol 1986; 30: 7–11

    Article  PubMed  CAS  Google Scholar 

  21. Sitar DS, Warren CP, Aoki FY. Pharmacokinetics and pharmacodynamics of bambuterol, a long-acting bronchodilator prodrug of terbutaline, in young and elderly patients with asthma. Clin Pharmacol Ther 1992; 52: 297–306

    Article  PubMed  CAS  Google Scholar 

  22. D’Alonzo GE, Smolensky MH, Feldman S, et al. Bambuterol in the treatment of asthma: a placebo-controlled comparison of once-daily morning vs evening administration. Chest. 1995; 107: 406–12

    Article  PubMed  Google Scholar 

  23. Fagerström P-O. Pharmacokinetics of terbutaline after parenteral administration. Eur J Resp Dis 1984; 65 Suppl. 134: 101–10

    Google Scholar 

  24. Ryrfeldt Å, Nilsson E, Tunek A, et al. Bambuterol: uptake and metabolism in guinea pig isolated lungs. Pharm Res 1988; 5: 151–5

    Article  PubMed  CAS  Google Scholar 

  25. Bodin NO, Hansson E, Ramsay CH, et al. The tissue distribution of 3H-terbutaline (Bricanyl®) in mice. Acta Physiol Scand 1972; 84: 40–7

    Article  PubMed  CAS  Google Scholar 

  26. Ryrfeldt Å, Ramsay CH. Distribution of terbutaline. Eur J Resp Dis 1984; 65 Suppl. 134: 63–72

    Google Scholar 

  27. Lindberg C, Roos C, Tunek A, et al. Metabolism of bambuterol in rat liver microsomes: identification of hydroxylated and demethylated products by liquid chromatography mass spectrometry. Drug Metab Dispos 1989; 17: 311–22

    PubMed  CAS  Google Scholar 

  28. Nyberg L. Pharmacokinetic properties of bambuterol in solution and tablets-basis for once daily dosage in asthma. Acta Pharmacol Toxicologica 1986; 59 Suppl. V: 229

    Google Scholar 

  29. Persson G, Baas A, Knight A, et al. One month treatment with the once daily oral β2-agonist bambuterol in asthmatic patients. Eur Respir J 1995; 8: 34–9

    Article  PubMed  CAS  Google Scholar 

  30. Burr ML, Charles TJ, Roy K, et al. Asthma in the elderly: an epidemiological survey. BMJ 1979; 1: 1041–7

    Article  PubMed  CAS  Google Scholar 

  31. Petrie GR, Chookang JY, Hassan WU, et al. Bambuterol: effective in nocturnal asthma. Respir Med 1993; 87: 581–5

    Article  PubMed  CAS  Google Scholar 

  32. Clemmensen IH, Pedersen BK, Ravn S, et al. Bambuterol: clinical effects of three doses of bambuterol once daily in asthmatic patients. Allergy 1988; 43: 573–6

    Article  PubMed  CAS  Google Scholar 

  33. Persson G, Gnosspelius Y, Anehus S. Comparison between a new once-daily, bronchodilating drug, bambuterol, and terbutaline sustained-release, twice daily. Eur Respir J 1988; 1: 223–6

    PubMed  CAS  Google Scholar 

  34. Fugleholm AM, Ibsen TB, Laxmyr L, et al. Therapeutic equivalence between bambuterol, 10mg once daily, and terbutaline controlled release, 5mg twice daily, in mild to moderate asthma. Eur Respir J 1993; 6: 1474–8

    PubMed  CAS  Google Scholar 

  35. Persson G, Pahlm O, Gnosspelius Y. Oral bambuterol versus terbutaline in patients with asthma. Curr Ther Res 1995; 56: 457–65

    Article  Google Scholar 

  36. Wempe JB, Tammeling EP, Postma DS, et al. Effects of budesonide and bambuterol on circadian variation of airway responsiveness and nocturnal symptoms of asthma. J Allergy Clin Immunol 1992; 90: 349–57

    Article  PubMed  CAS  Google Scholar 

  37. Gunn SD, Ayres JG, McConchie SM, et al. Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma. Eur J Clin Pharmacol 1995; 48: 23–8

    Article  PubMed  CAS  Google Scholar 

  38. Larsén K, Schmekel B. Tremor in healthy volunteers after bambuterol and terbutaline CR-tablets. Eur J Clin Pharmacol 1993; 45: 303–5

    Article  PubMed  Google Scholar 

  39. Deacon SP. Salbutamol and hypokalemia. Lancet 1976; I: 1302

    Article  Google Scholar 

  40. Leitch AG, Clancy LJ, Costello JF, et al. Effect of intravenous infusion of salbutamol on ventilatory response to carbon dioxide and hypoxia and on heart rate and plasma potassium in normal men. BMJ 1976; 1: 365–7

    Article  PubMed  CAS  Google Scholar 

  41. Wempe JB, Tammeling EP, Koëter GH, et al. Blood eosinophil numbers and activity during 24 hours: effects of treatment with budesonide and bambuterol. J Allergy Clin Immunol 1992; 90: 757–65

    Article  PubMed  CAS  Google Scholar 

  42. Fisher DM, Caldwell JE, Sharma M, et al. The influence of bambuterol (carbamylated terbutaline) on the duration of action of succinylcholine-induced paralysis in humans. Anesthesiology 1988; 69: 757–9

    Article  PubMed  CAS  Google Scholar 

  43. Staun P, Lennmarken C, Eriksson LI, et al. The influence of 10mg and 20mg of bambuterol on the duration of succinylcholine-induced neuromuscular blockade. Acta Anaesthesiol Scand 1990; 34: 498–500

    Article  PubMed  CAS  Google Scholar 

  44. Bang U, Viby-Mogensen J, Wirén JE, et al. The effect of bambuterol (carbamylated terbutaline) on plasma cholinesterase activity and suxamethonium-induced neuromuscular blockade in genotypically normal patients. Acta Anaesthesiol Scand 1990; 34: 596–9

    Article  PubMed  CAS  Google Scholar 

  45. Bang U, Viby-Mogensen J, Wirén JE. The effect of bambuterol on plasma cholinesterase activity and suxamethonium-induced neuromuscular blockade in subjects heterozygous for abnormal plasma cholinesterase. Acta Anaesthesiol Scand 1990; 34: 600–4

    Article  PubMed  CAS  Google Scholar 

  46. Asthma at night [editorial]. Lancet 1983; I: 220–2

    Google Scholar 

  47. Tilles SA, Nelson HS. Long-acting inhaled beta agonists. J Asthma 1995; 32: 397–404

    Article  PubMed  CAS  Google Scholar 

  48. Bhagat R, Kalra S, Swystun VA, et al. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108: 1235–39

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniel S. Sitar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sitar, D.S. Clinical Pharmacokinetics of Bambuterol. Clin-Pharmacokinet 31, 246–256 (1996). https://doi.org/10.2165/00003088-199631040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199631040-00002

Keywords

Navigation